
Topic
Biosimilars
Follow-on biologics, reference-product erosion, payer switching, launch sequencing, and specialty-channel uptake.

Pricing & Access· May 31, 2026 · 10 min read

Pricing & Access· May 31, 2026 · 9 min read
Payer-mandated biosimilar switch communication and nocebo risk
By Ran Chen#Biosimilars#Payer Policy#Formulary Strategy

Pricing & Access· May 31, 2026 · 13 min read
Retina buy-and-bill inventory risk when payer preference changes
By Ran Chen#Anti-VEGF#Ophthalmology#Buy and Bill

Biosimilars· May 27, 2026 · 9 min read
Actemra biosimilars access guide: IV vs SC routing and payer switching
By Ran Chen#Biosimilars#Immunology#HCPCS Coding

Biosimilars· May 27, 2026 · 11 min read
Lantus biosimilars and insulin glargine interchangeability guide

Biosimilars· May 27, 2026 · 9 min read
Lucentis biosimilars access guide for retina practices
By Ran Chen#Biosimilars#Anti-VEGF#Ophthalmology

Biosimilars· May 27, 2026 · 12 min read
Neulasta biosimilars coding and reimbursement guide
By Ran Chen#Biosimilars#HCPCS Coding#Oncology

Pricing & Access· May 27, 2026 · 10 min read
Opdivo Qvantig vs IV Opdivo access guide
By Ran Chen#Oncology#Prior Authorization#Payer Policy

Pricing & Access· May 27, 2026 · 12 min read
Prolia and Xgeva denosumab biosimilars guide
By Ran Chen#Biosimilars#Payer Policy#HCPCS Coding

Biosimilars· May 27, 2026 · 9 min read
Simponi and Simponi Aria biosimilars guide
By Ran Chen#Biosimilars#TNF Inhibitor#Immunology